GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tilray Brands Inc (NAS:TLRY) » Definitions » ROC (Joel Greenblatt) %

Tilray Brands (Tilray Brands) ROC (Joel Greenblatt) % : -50.58% (As of Feb. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Tilray Brands ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Tilray Brands's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -50.58%.

The historical rank and industry rank for Tilray Brands's ROC (Joel Greenblatt) % or its related term are showing as below:

TLRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -207.66   Med: -18.56   Max: 18.26
Current: -37.98

During the past 12 years, Tilray Brands's highest ROC (Joel Greenblatt) % was 18.26%. The lowest was -207.66%. And the median was -18.56%.

TLRY's ROC (Joel Greenblatt) % is ranked worse than
76.24% of 1065 companies
in the Drug Manufacturers industry
Industry Median: 7.85 vs TLRY: -37.98

Tilray Brands's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Tilray Brands ROC (Joel Greenblatt) % Historical Data

The historical data trend for Tilray Brands's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tilray Brands ROC (Joel Greenblatt) % Chart

Tilray Brands Annual Data
Trend Aug14 May15 May16 May17 May18 May19 May20 May21 May22 May23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.97 -18.56 -51.26 -53.10 -207.66

Tilray Brands Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -728.10 -51.39 -26.72 -23.53 -50.58

Competitive Comparison of Tilray Brands's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Tilray Brands's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tilray Brands's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tilray Brands's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Tilray Brands's ROC (Joel Greenblatt) % falls into.



Tilray Brands ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Nov. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(90.596 + 252.702 + 38.938) - (216.898 + 0 + 11.472)
=153.866

Working Capital(Q: Feb. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(89.542 + 244.139 + 71.672) - (209.763 + 0 + 3.182)
=192.408

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Tilray Brands for the quarter that ended in Feb. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Feb. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2023  Q: Feb. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-397.348/( ( (628.638 + max(153.866, 0)) + (596.236 + max(192.408, 0)) )/ 2 )
=-397.348/( ( 782.504 + 788.644 )/ 2 )
=-397.348/785.574
=-50.58 %

Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tilray Brands  (NAS:TLRY) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Tilray Brands ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Tilray Brands's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tilray Brands (Tilray Brands) Business Description

Address
265 Talbot Street West, Leamington, ON, CAN, N8H 5L4
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.
Executives
Denise M Faltischek officer: Chief Strategy Officer C/O THE HAIN CELESTIAL GROUP, INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Mitchell Gendel officer: Global General Counsel EMERALD HOLDING, INC., 100 BROADWAY, 14TH FLOOR, NEW YORK NY 10005
Irwin D Simon director, officer: President & CEO C/O THE HAIN CELESTIAL GROUP INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Carl A Merton officer: Chief Financial Officer C/O TILRAY, INC., 745 FIFTH AVENUE, SUITE 1602, NEW YORK NY 10151
Brendan Kennedy director 1920 EASTLAKE AVENUE E., SEATTLE WA 98105
James R. Meiers officer: Head of Canada C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David G. Hopkinson director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Thomas P. Looney director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Johann Michael Herhalt director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Jodi L. Butts director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David F Clanachan director TIM HORTONS INC., 874 SINCLAIR ROAD, OAKVILLE A6 L6K 2Y1
Renah Persofsky director 55 PRINCE ARTHUR AVENUE, #604, TORONTO A6 M5R 1B3
Jon Edward Levin officer: Chief Operating Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Michael C. Kruteck officer: Chief Financial Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Rebekah Dopp director 444 LENOX AVENUE, SOUTH ORANGE NJ 07079